Anemia Management in Chronic Kidney Disease

Initial Evaluation and Treatment

The American College of Cardiology recommends iron supplementation as the first-line treatment for anemia in chronic kidney disease, followed by erythropoiesis-stimulating agents (ESAs) if iron repletion fails to achieve target hemoglobin levels of 10-12 g/dL 1
Before initiating any anemia treatment, baseline tests should include complete blood count with absolute reticulocyte count, serum ferritin level, transferrin saturation (TSAT), and serum vitamin B12 and folate levels 1, 2

Iron therapy should be initiated when TSAT ≤30% and ferritin ≤500 ng/mL in patients not yet on ESA therapy, as ESAs increase iron utilization and can unmask or worsen iron deficiency 1, 4
For non-dialysis CKD patients, either intravenous iron or a 1-3 month trial of oral iron is appropriate, while for hemodialysis patients, proactive intravenous iron is superior to reactive strategies 1, 4, 5

ESA therapy should be initiated only after iron stores have been corrected, other reversible causes treated, and hemoglobin remains below 10 g/dL despite iron repletion, with a target hemoglobin level between 10-12 g/dL 1, 5, 6
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends against targeting hemoglobin >12 g/dL, as multiple trials demonstrate increased cardiovascular events and mortality with higher targets 3, 5, 1

Epoetin alfa (short-acting) and darbepoetin alfa (long-acting) are options for ESA therapy, with subcutaneous administration being more effective than intravenous for short-acting ESAs 4, 5, 6
Hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) offer convenience, particularly for non-dialysis CKD patients, and may improve iron utilization for erythropoiesis 5, 6

Active malignancy, history of stroke, and uncontrolled hypertension are critical contraindications for ESA use 1

Patients should be classified as ESA-hyporesponsive if hemoglobin does not increase from baseline after the first month of appropriate weight-based ESA dosing, and causes such as absolute or functional iron deficiency, infection, and severe hyperparathyroidism should be investigated 1, 2

Red blood cell transfusions should be avoided when possible to minimize allosensitization and transfusion-related risks, and considered only when ESA therapy is ineffective or immediate correction of anemia is required 1, 5